This clinical trial is focused on studying the effectiveness and safety of treatments for a condition called non-infectious uveitis. Uveitis is an inflammation of the middle layer of the eye, which can lead to vision problems. The study will explore the use of two medications, Adalimumab and Methotrexate, either on their own or in combination. Adalimumab is a type of medication known as an immunoglobulin, which helps to reduce inflammation by targeting specific proteins in the immune system. Methotrexate is a chemical medication that also helps to control inflammation and is often used in autoimmune diseases.

The purpose of this study is to compare how well patients respond to these treatments over a period of time. Participants will be randomly assigned to one of three groups: one group will receive Adalimumab, another will receive Methotrexate, and the third group will receive a combination of both medications. The study will last for up to 52 weeks, during which participants will have regular visits to monitor their response to the treatment. The goal is to see if the treatments can help maintain a good clinical response, which means reducing the symptoms of uveitis and preventing flare-ups of inflammation.

Throughout the study, participants will be closely monitored to ensure their safety and to assess the cost-effectiveness of the treatments. The study will also look at various aspects of the participants’ health and quality of life, such as changes in vision and any side effects experienced. By the end of the study, researchers hope to determine which treatment option is most effective for managing non-infectious uveitis.